Lipid-Lowering Drug Bezafibrate Significantly Reduces Incidence of Type 2 Diabetes

Research study leader Dr. Alexander Tenenbaum from Chaim Sheba Medical Center in Tel-Hashomer said “Our study has shown that bezafibrate can reduce the incidence of type 2 diabetes with a magnitude of benefit even better than other medications - 41 percent reduction during about 6 years. Moreover, bezafibrate also delayed the onset of diabetes by about 2 years.”

“It seems logical,” Tenenbaum added, that combining bezafibrate with other drugs, such as statins and metformin, might achieve even better results.

Bezafibrate lowers harmful triglycerides and raises “good” HDL-cholesterol and also reduces blood sugar levels.

The current study, Tenenbaum told Reuters Health, “reinforces the argument that management of atherogenic dyslipidemia in patients with obesity, metabolic syndrome and/or type 2 diabetes should be focused not just on LDL cholesterol, but on triglycerides and HDL cholesterol as well.”

Link []

Filed under Diabetes | Comment Below


Leave a Reply

Protected by Comment Guard Pro